

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/P8C8015C017CEN.html>

Date: March 2022

Pages: 114

Price: US\$ 2,000.00 (Single User License)

ID: P8C8015C017CEN

Abstracts

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cholangitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Primary Biliary Cholangitis (Other Diseases) pipeline landscape.

Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea.

Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cholangitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Primary Biliary Cholangitis (Other Diseases), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and

development history and latest news and press releases.

The Primary Biliary Cholangitis (Other Diseases) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 9, 4, 1, 9, 4 and 1 respectively.

Primary Biliary Cholangitis (Other Diseases) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cholangitis (Other Diseases).

The pipeline guide reviews pipeline therapeutics for Primary Biliary Cholangitis (Other Diseases) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Primary Biliary

Cholangitis (Other Diseases) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Primary Biliary Cholangitis (Other Diseases) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cholangitis (Other Diseases)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cholangitis (Other Diseases).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Primary Biliary Cholangitis (Other Diseases) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Overview
- Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Companies Involved in Therapeutics Development
- AbbVie Inc
- Abcuro Inc
- Albireo Pharma Inc
- Alexion Pharmaceuticals Inc
- Ascleptis Pharma Inc
- Avolynt Inc
- Calliditas Therapeutics AB
- CAMP4 Therapeutics Corp
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Cour Pharmaceuticals Development Co Inc
- CymaBay Therapeutics Inc
- Dr. Falk Pharma GmbH
- Escient Pharmaceuticals Inc
- Future Medicine Co Ltd
- Genfit SA
- GenKyoTex SA
- GentiBio Inc
- Gilead Sciences Inc
- Hanmi Pharmaceuticals Co Ltd
- HighTide Therapeutics Inc
- Kissei Pharmaceutical Co Ltd
- Kowa Co Ltd
- MediGene AG

Mirum Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Parvus Therapeutics Inc
PRISM Pharma Co Ltd
Selecta Biosciences Inc
Shaanxi Micot Technology Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Umecrine Cognition AB
Zydus Lifesciences Ltd
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Drug Profiles
A-3907 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ABC-008 - Drug Profile
Product Description
Mechanism Of Action
aldafermin - Drug Profile
Product Description
Mechanism Of Action
History of Events
ASC-42 - Drug Profile
Product Description
Mechanism Of Action
AVO-1681 - Drug Profile
Product Description
Mechanism Of Action
bezafibrate SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
budesonide DR - Drug Profile
Product Description
Mechanism Of Action
History of Events
bulevirtide - Drug Profile
Product Description
Mechanism Of Action
CNP-104 - Drug Profile

Product Description
Mechanism Of Action
History of Events
elafibranor - Drug Profile
Product Description
Mechanism Of Action
History of Events
EP-547 - Drug Profile
Product Description
Mechanism Of Action
History of Events
golexanolone - Drug Profile
Product Description
Mechanism Of Action
History of Events
HM-15211 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HTD-1801 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LJ-2698 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MT-2004 - Drug Profile
Product Description
Mechanism Of Action
norursodeoxycholic acid - Drug Profile
Product Description
Mechanism Of Action
Oligonucleotides for Primary Biliary Cholangitis - Drug Profile
Product Description
Mechanism Of Action
pemafibrate - Drug Profile
Product Description
Mechanism Of Action

PRI-724 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Primary biliary cholangitis - Drug Profile
Product Description
Mechanism Of Action
Primary Biliary Cholangitis (PBC) - Drug Profile
Product Description
Mechanism Of Action
History of Events
PVT-201 - Drug Profile
Product Description
Mechanism Of Action
remogliflozin etabonate - Drug Profile
Product Description
Mechanism Of Action
History of Events
RhuDex - Drug Profile
Product Description
Mechanism Of Action
History of Events
saroglitazar - Drug Profile
Product Description
Mechanism Of Action
History of Events
seladelpar lysine - Drug Profile
Product Description
Mechanism Of Action
History of Events
setanaxib - Drug Profile
Product Description
Mechanism Of Action
History of Events
tiomolibdate choline - Drug Profile
Product Description
Mechanism Of Action
History of Events
TQA-3526 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ursodiol - Drug Profile

Product Description

Mechanism Of Action

History of Events

volixibat potassium - Drug Profile

Product Description

Mechanism Of Action

History of Events

ZG-5266 - Drug Profile

Product Description

Mechanism Of Action

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Dormant Projects

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Discontinued Products

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Product Development Milestones

Featured News & Press Releases

Feb 15, 2022: First patient randomized in pivotal TRANSFORM study with setanaxib

Feb 01, 2022: Liver Institute Northwest participating in RESPONSE, a global phase 3 clinical research study evaluating an investigational therapy for the treatment of Primary Biliary Cholangitis (PBC)

Dec 10, 2021: Zydus announces EPICS-III phase 2(b)/3 adaptive pivotal clinical trial of Saroglitazar Mg in PBC

Nov 15, 2021: Gannex announces China NMPA approved phase II and III protocols of ASC42, an FXR agonist, for treatment of primary biliary cholangitis

Nov 15, 2021: CymaBay Therapeutics long-term open label study finds treatment with seladelpar for two years improves key liver biomarkers in patients with PBC

Nov 11, 2021: CymaBay Therapeutics to host post-AASLD key opinion leader webinar on seladelpar for primary biliary cholangitis

Nov 02, 2021: New clinical data on GENFIT's investigational compound Elafibranor to be presented at AASLD The Liver Meeting

Nov 02, 2021: Pinnacle Clinical Research, PLLC participating in RESPONSE, a global phase 3 clinical research study evaluating an investigational therapy for the treatment of Primary Biliary Cholangitis (PBC)

Oct 01, 2021: CymaBay Therapeutics announces presentations at The Liver Meeting 2021

Sep 06, 2021: Gannex announces clinical trial application of ASC42, an FXR agonist, for treatment of primary biliary cholangitis accepted by China NMPA

Aug 09, 2021: Calliditas receives FDA Fast Track Designation for setanaxib in PBC

Jul 21, 2021: European Medicines Agency grants Orphan Drug Designation to Saroglitazar Mg for the treatment of patients with Primary Biliary Cholangitis (PBC)

Jun 24, 2021: Korea-US innovative bio-drug confirms the possibility of treating various rare liver diseases

Jun 23, 2021: Mirum Pharmaceuticals presents analyses from volixibat at the EASL International Liver Congress 2021

Jun 21, 2021: CymaBay Therapeutics presents positive PBC data at the International Liver Congress 2021

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by AbbVie Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Abcuro Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Albireo Pharma Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Alexion Pharmaceuticals Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Ascleptis Pharma Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Avolynt Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Calliditas Therapeutics AB, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by CAMP4 Therapeutics Corp, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Cour Pharmaceuticals Development Co Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by CymaBay Therapeutics Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Dr. Falk Pharma GmbH, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Escient Pharmaceuticals Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Future Medicine Co Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Genfit SA, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by GenKyoTex SA, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by GentiBio Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Gilead Sciences Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by HighTide Therapeutics Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Kissei Pharmaceutical Co Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Kowa Co Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by MediGene AG, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Mirum Pharmaceuticals Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by NGM Biopharmaceuticals Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Parvus Therapeutics Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by PRISM Pharma Co Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Selecta Biosciences Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Shaanxi Micot Technology Co Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Umecrine Cognition AB, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Zydus Lifesciences Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Dormant Projects, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Dormant Projects, 2022
(Contd..1)

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/P8C8015C017CEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P8C8015C017CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

